

IUBMB Enzyme Nomenclature

EC 3.5.4.6

Common name: AMP deaminase

Reaction: AMP + H₂O = IMP + NH₃

For diagram [click here](#).

Other name(s): adenylic acid deaminase; AMP aminase; adenylic deaminase; adenylate deaminase; 5-AMP deaminase; adenosine 5-monophosphate deaminase; 5-adenylate deaminase; adenylic deaminase; 5-adenylyc acid deaminase; adenosine monophosphate deaminase; adenylate aminohydrolase; adenylate desaminase; adenosine 5-phosphate aminohydrolase; 5-adenylate deaminase

Systematic name: AMP aminohydrolase

Comments: cf. [EC 3.5.4.17](#) adenosine-phosphate deaminase.

Links to other databases: [BRENDA](#), [EXPASY](#), [GTD](#), [KEGG](#), [ERGO](#), CAS registry number: 9025-10-9

References:

1. Kalckar, H.M. Differential spectrophotometry of purine compounds by means of specific enzymes. III. Studies of the enzymes of purine metabolism. *J. Biol. Chem.* 167 (1947) 461-475.
2. Lee, Y.-P. 5'-Adenylic acid deaminase. I. Isolation of the crystalline enzyme from rabbit skeletal muscle. *J. Biol. Chem.* 227 (1957) 987-992.
3. Lee, Y.-P. 5'-Adenylic acid deaminase. II. Homogeneity and physicochemical properties. *J. Biol. Chem.* 227 (1957) 993-998.
4. Lee, Y.-P. 5'-Adenylic acid deaminase. III. Properties and kinetic studies. *J. Biol. Chem.* 227 (1957) 999-1007.
5. Mendicino, J. and Muntz, J.A. The activating effect of adenosine triphosphate on brain adenylic deaminase. *J. Biol. Chem.* 233 (1958) 178-183.
6. Turner, D.H. and Turner, J.F. Adenylic deaminase of pea seeds. *Biochem. J.* 79 (1961) 143-147.
7. Weil-Malherbe, W. and Green, R.H. Ammonia formation in brain. 2. Brain adenylic deaminase. *Biochem. J.* 61 (1955) 218-224.

[EC 3.5.4.6 created 1961]

Return to [EC 3.5.4 home page](#)

Return to [EC 3.5 home page](#)

SPN

	<u>Tetragonal - Disphenoidal</u>	(4)	$\bar{4}$ and $P\bar{4}$	<p>P = Primitive Lattice. I = Body Centered Lattice.</p> <p>$\bar{4}$ = Rotoinversion Axis. 4,2 = Symmetry Axis (360/n). 4_{1,2,3} = Screw Axis.</p> <p>a,b,c = Perpendicular Glide Planes. m,n = Oblique Glide Planes.</p>
	<u>Tetragonal - Pyramidal</u>	(4)	I4, I4 ₁ , P4, P4 ₁ , P4 ₂ , and P4 ₃	
	<u>Tetragonal - Dipyramidal</u>	(4/m)	I4/m, I4 ₁ /a, P4/m, P4/n, P4 ₂ /m, and P4 ₂ /n	
	<u>Tetragonal - Scalenohedral</u>	($\bar{4}$ 2m)	$\bar{4}2d$, $\bar{4}2m$, $\bar{4}c2$, $\bar{4}m2$, P421c, P42 ₁ m, P42c, P42m, P4b2, P4c2, P4m2, and P4n2	
	<u>Tetragonal - Ditetragonal Pyramidal</u>	(4mm)	I4/mcm, I4/mmm, I4 ₁ /acd, I4 ₁ /amd, P4/mbm, P4/mcc, P4/mmm, P4/mnc, P4/nbm, P4/ncc, P4/nmm, P4/nnc, P4 ₂ /mbc, P4 ₂ /mcm, P4 ₂ /mmc, P4 ₂ /nmn, P4 ₂ /nbc, P4 ₂ /ncm, P4 ₂ /nmc, and P4 ₂ /nnm	
	<u>Tetragonal - Trapezohedral</u>	(4 2 2)	I4 ₁ 22, I422, P4 ₁ 2 ₁ 2, P4 ₁ 22, P42 ₁ 2, P422, P4 ₂ 2 ₁ 2, P4 ₂ 22, P4 ₃ 2 ₁ 2, and P4 ₃ 22	
	<u>Tetragonal - Ditetragonal Dipyramidal</u>	(4/m 2/m 2/m)	I4 ₁ cd, I4 ₁ md, I4cm, I4mm, P4 ₂ bc, P4 ₂ cm, P4 ₂ mc, P4 ₂ nm, P4bm, P4cc, P4mm, and P4nc	

SPAT



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
14.08.2002 Bulletin 2002/33

(51) Int Cl.7: **G06F 17/00, C12N 9/78**

(43) Date of publication A2:
19.06.2002 Bulletin 2002/25

(21) Application number: **01309996.5**

(22) Date of filing: **29.11.2001**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
 Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **13.12.2000 GB 0030424**

(71) Applicants:
 • **Pfizer Limited**
Sandwich, Kent CT13 9NJ (GB)
 • **PFIZER INC.**
New York, N.Y. 10017 (US)


(72) Inventors:
 • **Bazin, Richard J., c/o Pfizer Global Res. & Dev.**
Sandwich, Kent CT13 9NJ (GB)
 • **McDonald, Graeme A.,**
c/o Pfizer Global Res. & Dev.
Sandwich, Kent CT13 9NJ (GB)
 • **Phillips, Christopher,**
c/o Pfizer Global Res.&Dev.
Sandwich, Kent CT13 9NJ (GB)

(74) Representative: **Hayles, James Richard**
UK Patent Department,
Pfizer Limited,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(54) **Adenosine monophosphate deaminase crystal structure**

(57) A 2.2 Å crystal structure of rabbit AMP deaminase, an integral enzyme of purine nucleotide interconversion, has been determined, in an unligated state and with an inhibitor bound. The present invention further discloses the use of x-ray crystallographic data for identification and construction of possible therapeutic compounds in the treatment of various disease conditions. The sequence of rabbit AMP deaminase is also disclosed.

Figure 1





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 01 30 9996

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D,X	SMILEY K.L., BERRY A.J., AND SUELTER C.H.: "An improved purification, crystallization, and some properties of rabbit muscle 5'-adenylic acid deaminase" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 242, no. 10, 25 May 1967 (1967-05-25), pages 2502-2506, XP001064797 * the whole document *	22	G06F17/00 C12N9/78
X	DATABASE GENBANK 'Online! NCBI; 31 October 2000 (2000-10-31) "Homo sapiens adenosine monophosphate deaminase 1 (AMPD1), mRNA" Database accession no. NM_000036 XP002198763 * abstract *	25,36	
D,A	WO 94 18200 A (GENSIA INC) 18 August 1994 (1994-08-18) * the whole document *	25-29	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/does not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search MUNICH		Date of completion of the search 24 May 2002	Examiner Schwachtgen, J-L
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03 02 (10/03/07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 01 30 9996

Claim(s) not searched:
30-33

Reason for the limitation of the search:

Claims 30-33 are directed to compounds obtained by a rational drug design screening method. However, no such compounds are defined in the application. No meaningful search can be carried out for such reach-through claims because their scope is purely speculative and open-ended, contrary to the requirements of Articles 84 and 83 EPC.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 9996

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

24-05-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9418200	A	18-08-1994	AU 6134994 A 29-08-1994
		CA 2154577 A1 18-08-1994	
		EP 0683781 A1 29-11-1995	
		JP 8506344 T 09-07-1996	
		MX 9400874 A1 31-08-1994	
		WO 9418200 A1 18-08-1994	
		US 5731432 A 24-03-1998	

EPO FORM P0439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82